The premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers, the Society of Gynecological Oncology (SGO) contributes to the advancement of women’s cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members, and collaborating with other domestic and international organizations. SGO has 2000 members representing the entire gynecologic oncology team in the United States and abroad.
The SGO Annual Meeting on Women’s Cancer brings together gynecologic oncologists from all over the world to share the latest research and practice innovations in the treatment of gynecologic malignancies. This intensive, comprehensive 4-day event offers continuing education credits and features many educational sessions in a variety of didactic and interactive formats so professionals can stay on top of advancements in the field and provide the best, evidence-based care for patients.
The 2018 SGO Annual Meeting on Women’s Cancer had a record-setting attendance, with 2525 registering for the meeting that took place in March in New Orleans. Sessions focused on the interpretation and implementation of contemporary research findings on the prevention of and screening for gynecologic cancers. Speakers also touched on the significance of novel approaches to the medical and surgical management of gynecologic cancers within the context of the current standard of care and how to integrate new therapies into clinical practice in an evidence-based manner.
ASCO Alternative Payment Model Yields Savings in Ovarian Cancer
The American Society of Clinical Oncology’s Patient-Centered Oncology Payment model helps achieve costs savings in ovarian cancer when hospitalizations are reduced during the active treatment period.
Gynecologic Cancers Significantly Underfunded Compared With Other Cancers
In comparison to the funding and survival rate of many other cancer types, funding for ovarian, cervical, and uterine cancer does not align with their survival rates.
Study: Cervical Cancer Screening Guidelines Need Reconsideration
The current recommended age of 65 years to stop cervical cancer screening should be reconsidered.
Ovarian Cancer Health Disparities May Be Improved Through Clinical Trial Participation
Participation in clinical trials may help overcome health disparities in the treatment of advanced or recurrent ovarian cancer.
Comparative Effectiveness Study Examines Multiple PARP Inhibitors for BRCA-Mutated Ovarian Cancer
A featured poster session detailed the results of a study comparing the efficacy and tolerability of PARP inhibitors as maintenance treatment in BRCA-mutated platinum-sensitive relapsed ovarian cancer.
